CompletedPhase 4NCT06094920

Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial

Studying MODY

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University Medical Center Groningen
Principal Investigator
Hiddo Lambers Heerspink
University Medical Center Groningen
Intervention
Empagliflozin 10 MG(drug)
Enrollment
12 target
Eligibility
18 years · All sexes
Timeline
20242025

Study locations (1)

Collaborators

Boehringer Ingelheim

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06094920 on ClinicalTrials.gov

Other trials for MODY

Additional recruiting or active studies for the same condition.

See all trials for MODY

← Back to all trials